Vara wins CE mark for breast AI

Vara said on September 2 that it had received CE certification under the European Union Medical Device Regulation for autonomous triage in organized breast-cancer screening. The Berlin company said the product is classified as a Class IIb medical device and is the first breast AI certified to report clearly normal screening exams without radiologist review. The certification was supported by the PRAIM study, a prospective trial conducted at 12 sites in Germany. Bayesian Health separately said on September 2 that Medicare had approved a New Technology Add-on Payment for its FDA-cleared continuous AI sepsis monitor starting October 1, 2026. ### What exactly did Vara get cleared to do? CE certification under the EU MDR allows Vara's autonomous triage system to be used in organized breast screening programs in Europe, subject to local clinical adoption and national rules. Vara said the system can classify some mammography exams as clearly normal and let those cases be reported without a radiologist reading them first. (finance.yahoo.com) Class IIb is a higher-risk device category under the EU medical-device regime than many clinical decision-support tools. Vara said its certification covers autonomous triage rather than only reader-assist functions, which is why the approval stands out in breast screening. ### How large was the evidence package behind the CE mark? (finance.yahoo.com) The PRAIM study evaluated 461,818 screening examinations involving asymptomatic women aged 50 to 69 across 12 German sites, according to Vara and secondary coverage of the certification. Vara said the study showed the system's cancer-detection rate was noninferior and statistically superior to the control group. (finance.yahoo.com) Nature Medicine published PRAIM last year, according to trade coverage cited in reports on the CE mark. Vara said the study formed the core of the real-world evidence package used to support autonomous-triage certification. ### What is ATMON, and why did Vara highlight it? ATMON is Vara's safety platform for real-time supervision of the autonomous AI, the company said. (crbcnews.com) Vara said the system monitors AI performance, hardware, system health and site-level signals, and is built on seven years of real-world monitoring. Jonas Muff, Vara's chief executive and co-founder, said in company-linked coverage that model performance can shift outside study conditions. (mpo-mag.com) Vara said it plans to license ATMON separately as well as deploy it with its own autonomous triage product. ### Why is Bayesian Health part of the same conversation? Bayesian Health said on September 2 that its FDA-cleared continuous AI sepsis monitor had been approved for Medicare's New Technology Add-on Payment under the FY 2027 inpatient payment rule. (yahoo.com) The company said hospitals using the monitor can receive additional reimbursement for eligible inpatient cases beginning October 1, 2026. Bayesian Health had said in May that the sepsis flagging device received FDA 510(k) clearance, which it described as the first continuous AI sepsis monitor to do so. The NTAP decision adds a payment pathway after the regulatory clearance, making the product eligible for hospital reimbursement in Medicare inpatient use. (prnewswire.com) ### What happens next in Europe and the United States? Europe is the next market for Vara's rollout. Vara said autonomous triage is now available to screening programs across Europe, with use depending on national guidelines and clinical readiness at each site. October 1, 2026 is the next operational date for Bayesian Health. (prnewswire.com) On that date, hospitals treating eligible Medicare inpatients can begin claiming the add-on payment for use of the company's sepsis monitor, according to the company. (prnewswire.com) (mpo-mag.com)